Anti-angiogenic strategies: from basic science to clinical applications
|
|
- Dennis Williamson
- 8 years ago
- Views:
Transcription
1 SFB-824 Symposium Alpbach Anti-angiogenic strategies: from basic science to clinical applications Dr. med. Andreas Fischer Joint Research Division Vascular Biology Medical Faculty Mannheim, University of Heidelberg, and German Cancer Research Center (DKFZ) Heidelberg (Director: Prof. Dr. Hellmut G. Augustin) Alpbach, E15.5 mouse embryos Coll. with E. Lang, P.M. Jakob; Dep. of Physics, Würzburg [Bruker Avance 500 spectrometer (11.7 Tesla; 500 MHz)]
2 Physiological angiogenesis and blood vessels National Cancer Institute Pathophysiological angiogenesis and blood vessels In situ tumor tumor stimulates angiogenesis Tumor growth and metastasis
3 Strategies to inhibit tumor angiogeneis More than 100 substances are currently in different clinical trials Anti-angiogenic substances Substances for vascular targeting MMP Inhibitors Pharmacological inhibitor Signalling antiinvasive substances Antiadhesive substances substances with unknown targets Thalidomid 2-Methoxyestradiol AGM1470 CAI α-vegf signalling α-integrin Endogenous inhibitors Angiostatin Endostatin Tumstatin Interferon-α Interleukin-12 Thrombospondin α-vegf-r; α-basalmembrane Immunotargeting-substances Pharmacological substances Combretastatin CM101 VEGF and its receptors VEGF-A: Receptors 1 & 2 Angiogenesis VEGF-B & PlGF: Receptor 1 Pathological angiogenesis (?) VEGF-C & VEGF-D: Receptor 3 (& 2) Lymphangiogenesis
4 upstream factors: mtor inhibitors Torisel (Temsirolismus) Afinitor (Everolimus) Strategies to inhibit VEGF VEGF production: (Antisense, Aptamer) Macugen (Pegaptanib) Veglin (sirna) Aflibercept (VEGF-Trap) Tumor cell Growth factors produced by tumors, e.g. VEGF Avastin (Bevacizumab) Lucentis (Ranibizumab) soluble receptors antibodies VEGF-receptors Sutent (Sunitinib) Nexavar (Sorafenib) Votrient (Pazopanib) Recentin (Cediranib) Axitinib Vatalanib XL184 X Blockade of receptor activation DC101 IMC-18F1 Endothelial cells VEGF neutalizing antibody Avastin (Bevacizumab) Avastin is a recombinant humanized antibody against VEGF-A VEGF Avastin binds and neutralizes VEGF Avastin Yuan et al., PNAS 1996
5 VEGF neutralizing antibody Avastin (Bevacizumab) Phase III trial (Roche and Genentech) 815 patients with advanced colorectal carcinomas Irinotecan/5-FU/FA (IFL) ± Avastin Increase of survival rate from 15.6 months to 20.3 months Progression free survival survival Hurwitz et al, NEJM, 2003 Bevacizumab therapy in metastatic breast cancer Avastin increases progression-free survival but not overall survival Miller et al NEJM 2007; 357: 2666
6 Approved indications for Bevacizumab (Avastin ) Late stage: colorectal cancer breast cancer non-small cell lung cancer kidney cancer (RCC) gliobastoma (only in USA) A series of phase III studies for other indications are ongoing. Soluble VEGF receptors - VEGF-Trap (Aflibercept) Fusion protein consisting of VEGFR1 and VEGFR2 domains binds to VEGF-A, VEGF-B, PlGF Aflibercept (VEGF-Trap ) (Regeneron / Bayer-Schering) Results of Phase III studies for lung and colorectal cancer expected in 2011 Phase III study for macula degeneration ongoing Holash et al., PNAS. 2002
7 Blocking VEGF-receptors VEGF VEGF binding domain Sunitinib Inhibition by: cell membrane P- P- -P -P Tyrosine kinase activity Sorafenib (Nexavar,Bayer-Schering) Sunitinib (Sutent, Pfizer) Pazopanib (Votrient, GSK) Cediranib (Recentin, AstraZeneca) Vatalanib (Novartis/Schering) Axitinib (Pfizer) XL184 (Exelixis) Angiogenesis Problems with Receptor tyrosine kinase inhibitors: Specificity BRK Kit PDGFR VEGFR courtesy: Christoph Schächtele (
8 Sorafenib Sorafenib (Nexavar, BAY , Bayer-Schering / Onyx) Inhibits VEGFR2, VEGFR3, PDGFRβ, Raf kinase (MAPK pathway), c-kit, SCF, Flt-3, RET Approved for renal cell carcinoma and hepatocellular carcinoma Wilhelm et al., Nat Reviews Drug Discovery, (5) 2006 Drevs. UNI-MED Verlag Sorafenib Phase-III study (advanced renal cell carcinoma): Sorafenib prolongs progression-free survival Wilhelm et al. Nature Reviews Drug Discovery 5, (October 2006) doi: /nrd2130
9 mtor inhibitors mtor is critical for cell division, survival, metabolism and also for induction of VEGF expression Inhibitors of mtor should affect tumor cells and angiogenesis Everolimus (Afinitor (oncology), Certican (transplantation), RAD001, Novartis) approved for advanced renal cell carcinoma (EU 8/2009) oral application also used on coronary stents to prevent stenosis Temsirolimus (Torisel, CCI-779, Wyeth) approved for advanced renal cell carcinoma (EU 11/2007) i.v. application VTA: vascular targeting agents Concept: Directed against existing tumor vessels VTAs cause disruption or occlusion of tumor vessels esp. in the center of the tumor massive hypoxia and necrosis of tumor cells. However: not all tumor cells are dying target endothelial tubulin Thorpe., Clin. Cancer Res.; Vol. 10, ; 2004
10 Effects of anti-angiogenic therapy in humans Treatment of malignant diseases: 1) Monotherapy leads to decrease in vessel density but is almost ineffective in terms of survival, progression-free survival WHY? 2) In contrast, anti-angiogenic therapy can synergize with classical chemotherapy (and radiation). WHY? Normal colorectal mucosa Adjacent colorectal tumor From: Molls and Vaupel, eds. Blood Perfusion and Microenvironment of Human Tumors, 2002 Vessel normalization If anti-angiogenic therapy would lead to massive destruction of tumor vessels: -more hypoxia - less perfusion decreased delivery of chemotherpeutics to tumor cells However: the rate of perfusion increases! during anti-angiogenic treatment Concept: Anti-angiogenic therapy leads to pruning of immature vessels, but also to a normalization of the remain vessels Jain, Science, Vol 307, 7 Jan 2005
11 Vessel normalization Please note: VEGF is a potent permeability factor! Jain, Science, Vol 307, 7 Jan 2005 Jain, Science, Vol 307, 7 Jan 2005
12 Resistance against anti-angiogenic therapy Still poorly understood, possible reasons: Production of higher VEGF levels and/or of other vascular growth factors or receptors: VEGF-B, PlGF, FGF, PDGF, VEGFR3, Nrp1, Nrp2, inflammatory cytokines, Normalized vessels (J Exp Med Mar 15;207(3): ) Tumor infiltration with bone marrow derived myeloid cells (CD11b + Gr1 + ) Targets: Angiopoetins Hypoxia sensors Notch signaling Pericytes PlGF MMPs Integrins Some novel strategies Fischer and Gessler, Nucl Acids Res Inhibits endothelial proliferation, migration, sprouting, branching, tip cell formation Promotes arterial fate, represses venous fate
13 The tip cell / stalk cell concept tip cells: sense a VEGF gradient with their filopodia migrate towards the source of VEGF do rarely proliferate form no lumen stalk cells: follow the tip cells proliferate to elongate the sprout form a lumen Gerhardt et al., The Journal of Cell Biology, Volume 161, Number 6, June 23, Which cell will become the tip cell? Why do the neighbouring cells become stalk cells? VEGF induces the Dll4 gene in tip cells Dll4 activates the Notch receptor in neighbouring cells Notch signaling prevents the adoption of a tip cell fate Phng and Gerhardt; Dev Cell Feb;16(2): Roca and Adams; Genes Dev Oct 15;21(20):
14 Notch signaling during cardiovascular development Hey1/L double knockout Loss of Hey2: - cardiac hypertrophy, ectopic ANF expression - increased length of the AV canal -congentialheart defects Loss of Hey1/L -congentialheart defects - decreased EMT Loss of Dll4, Notch1 or Hey1/2 - lethal angiogenesis defects - defective arterial differentiation - decreased EMT -heartdefects Hey1/2 double knockout control Gessler et al., Curr Biol., 2002; Fischer et al., Genes & Dev. 2004; Fischer et al., Mamm Genome, 2004; Fischer et al., Mol Cell Biol, 2005; Ruthenberg, Fischer et al, Development, 2006; Diez et al, Exp Cell Res, 2007; Fischer et al, Circ Res, 2007 Is Dll4-Notch signaling a potential target for antiangiogenic therapy? Nature. Vol /28 December 2006
15 Tools to block Notch signaling Gamma-secretase inhibitors Monoclonal antibodies against ligands and receptors Soluble ligands Nature, Vol April 2010 Nature Feb 11;463(7282):E6-7. Pathological angiogenesis Tumors Rheumatoid arthritis Ischemic Retinopathies Age-dependent macular degeneration Chronic transplant rejection Psoriasis Atherosclerosis Restenosis Obesity Pulmonary hypertension Chronic respiratory diseases Cerebral ischemia Dementia Vascular malformations Newsletter Anti-Angiogenese, Nr. 2, 6/2008
16 anti-angiogenic therapy of non-malignant diseases Age-related macula degeneration [subfoveal choroidal neovascularisation] Ranibizumab (Lucentis, Novartis): recombinant, humanized, monoclonal antibody (Fab fragment). Monthly intravitreal injections: reduced risk of visual acuity loss Effect of VEGF inhibition on neovascular AMD in patients Rosenfeld et al NEJM October 6th 2006 Alternative: Pegaptanib (Macugen, Pfizer, OSI Pharmaceuticals) Aptamer against VEGF Intravitreal injections every 6 weeks
17 Obesity and potential new applications: Y. Cao and potential new applications: Vascular malformations Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. (Nat Med Apr;16(4):420-8.) Sorafenib as a potential drug for cerebral cavernous malformations (Wüstehube et al., PNAS, in press) radiopaedia.org
18 CCM: Cerebral cavernous malformations berry-like bulk of enlarged microvessels often lacking pericytes 0.5% of human population is affected (range 1:200 1:1000) symptoms: headaches, seizures, focal neurological deficits, hemorrhage Cause: loss of CCM1, CCM2 or CCM3 in endothelial cells Lancet Neurol 2007; 6: J. Medical Genetics CCM: A novel animal model Xenotransplantation of human endothelial cells (HUVEC) into SCID mice (Alajati et al.2008 Nature Methods and Laib et al.2009 Nature Protocols) Stable lentiviral shrna mediated knockdown of CCM1 in HUVEC
19 CCM: Anti-angiogenic therapy? Summary Anti-angiogenic therapy is effective in non-malignant and malignant diseases For tumor treatment anti-angiogenic therapy works best in combination with classical chemotherapy Anti-angiogenic therapy causes partial regression of tumor vessels (and partially also healthy vessels, esp. fenestrated capillaries) Anti-angiogenic therapy leads to vessel normalization better perfusion of tumors, less hypoxia, better drug delivery
20 Fischer laboratory Joycelyn Wüstehube Sven Liebler Gordian Adam Caroline Berger Rene Brütsch Stefanie Herberich Wen-Jen Yang Anja Telzerow DKFZ Hellmut Augustin Arne Bartol Univ. of Würzburg Manfred Gessler Svenja Meierjohann Toni Wagner Neurosurgery, Essen Ulrich Sure Yuan Zhu Human Genetics, Greifswald Ute Felbor Grenoble Daniel Bouvard Corinne Albiges-Rizo Funding: DFG (Fi1568/1-1; SFB/TR23; GRK880) Universität Heidelberg (Med. Fak. Mannheim; Exzellenzinitiative) DKFZ - Israel - Kooperation
Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma
g Tumor Res. Basel, Karger, 2014, vol 41, pp 98 112 (DOI: 10.1159/000355906) Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma Marc Pracht Dominik Berthold Medical Oncology Unit,
More informationHow To Understand The Effects Of A Drug On Your Health
Farmacologia degli inibitori TK e mtor Romano Danesi Professore ordinario di Farmacologia UOC Farmacologia Universitaria Azienda Ospedaliero-Universitaria Pisana Dipartimento di Medicina Interna Università
More informationDrug treatments for kidney cancer
James Whale Fund for Kidney Cancer Drug treatments for kidney cancer Before your doctors can discuss treatment options with you they need to know how far your cancer has progressed. Staging is used to
More informationAvastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022
Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and
More informationWhat is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
More informationCancercare Connect Booklet Series. Renal Cell Cancer. www.cancercare.org
Cancercare Connect Booklet Series Treatment Update Renal Cell Cancer www.cancercare.org Treatment Update Renal Cell Cancer Table of Contents The CancerCare Connect Booklet Series offers up-to-date, easy-to-read
More informationThe New Kid on the Block for Advanced Renal Cell Carcinoma
The New Kid on the Block for Advanced Renal Cell Carcinoma Wyeth Pharmaceuticals recently launched Torisel (temsirolimus), a targeted, first-in-class mtor inhibitor. This new treatment for metastatic renal
More informationLung Cancer Research: From Prevention to Cure!
Lung Cancer Research: From Prevention to Cure! Ravi Salgia, M.D, Ph.D Associate Professor of Medicine Director, Thoracic Oncology Research Program Department of Medicine Section of Hematology/Oncology
More informationPROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S.
PROSPETTIVE FUTURE NEL TRATTAMENTO MEDICO DEL mrcc Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. Candiolo Future strategies in mrcc Improve therapeutic
More informationAn Informational Guide to CENTRAL RETINAL VEIN OCCLUSION
Science of CRVO www.scienceofcrvo.org An Informational Guide to CENTRAL RETINAL VEIN OCCLUSION This brochure will guide you in understanding CRVO and the treatment options available to prevent vision loss.
More informationGENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
More informationFDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema
Media Release Basel, 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema First major treatment advance in more than 25 years for sight-threatening condition
More informationA disease of populations of cells that live, divide, invade and spread without regard to normal limits
1 Targeted Cancer Therapies Mark McKeage Medical Oncology Specialist Professor in Clinical Pharmacology 2 Cancer Definition- A disease of populations of cells that live, divide, invade and spread without
More informationTechnology Assessment Report commissioned by the NHS R&D HTA Programme on behalf of the National Institute for Health and Clinical Excellence
Technology Assessment Report commissioned by the NHS R&D HTA Programme on behalf of the National Institute for Health and Clinical Excellence Protocol 26 October 2007 PROJECT TITLE Bevacizumab, sorafenib
More informationPublic-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics
EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC
More informationAnti-angiogenesis Treatment
Anti-angiogenesis Treatment The search for better cancer drugs Today we are better able to treat cancer than ever. More than half of all people with cancer now live at least 5 years after being diagnosed.
More informationGene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press
Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction
More informationExelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
More informationa Phase 2 prostate cancer clinical trial is ongoing. Table 2: Squalamine vs Standard-of-care literature
PRODUCT FACT SHEET Spring 2007 MISSION STATEMENT Genaera Corporation is a biopharmaceutical company with a focus on metabolic and respiratory diseases. The compounds in the Genaera pipeline address signal
More informationNew Directions in Treatment of Ovarian Cancer. Amit M. Oza Princess Margaret Hospital University of Toronto
New Directions in Treatment of Ovarian Cancer Amit M. Oza Princess Margaret Hospital University of Toronto Newly diagnosed: scenario Ist line Surgery chemotherapy Cure If can t cure can we turn into chronic
More informationTargeted Molecular Therapy for Renal Cell Carcinoma: Impact on Existing Treatment Paradigms
Targeted Molecular Therapy for Renal Cell Carcinoma: Impact on Existing Treatment Paradigms Wolfram Samlowski, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then
More informationMonoclonal antibody (mab) products are currently a fast
Antibody Monoclonal Therapeutics Janice M. Reichert, Ph.D. Monoclonal antibody (mab) products are currently a fast growing category of drugs. Like antibodies produced naturally by the human immune system,
More informationInflammatory Cytokine-induced Expression of Vasohibin-1 by Rheumatoid Synovial Fibroblasts
9 6 6 958 Inflammatory Cytokine-induced Expression of Vasohibin- by Rheumatoid Synovial Fibroblasts a b c a a a a d e a* a a b c d e 5 6 6 9 5 56 67 7 ʼ ʼ ʼ ʼ ʼ ʼ ʼ ʼ 5 6 6 ʼ 5 75 989 6 69 8 95 56 56896
More informationFARMACI PERSONALIZZATI PER
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI FONDAZIONE G. Pascale NAPOLI SC Biologia Cellulare e Bioterapie CENTRO RICERCHE ONCOLOGICHE MERCOGLIANO (AV) Laboratorio di Farmacogenomica FARMACI
More informationBNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED
ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination
More informationdrugs in development CuraScript Specialty Pharmacy Management Guide & Trend Report
CuraScript Specialty Pharmacy Management Guide & Trend Report Drugs in Development There are currently more than 324 drugs in development for nearly 150 disease states. These potential new medications
More informationCellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
More informationUnderstanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient
Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that
More informationPathophysiology of bone metastasis : how does it apply to pain treatment in palliative care? JP Vuillez, Grenoble, France
Pathophysiology of bone metastasis : how does it apply to pain treatment in palliative care? JP Vuillez, Grenoble, France Bone metastases 70 % of prostate and breast cancers 30 % of lung, bladder and thyroid
More informationCo-pay assistance organizations offering assistance
Acromegaly Acute Exacerbations of Multiple Sclerosis Acute Porphyrias Advanced Idiopathic Parkinson' s Disease Age-Related Macular Degeneration www.theassistancefund.org Alcohol Dependence Alpha-1 Antitrypsin
More informationHistopathology and prognosis in renal cancer
Histopathology and prognosis in renal cancer Granular cell Granular cell Granular cell Granular cell Clear cell Chromophobe cell Papillary type 2 Luca Mazzucchelli Istituto cantonale di patologia, Locarno
More informationNieuwe ontwikkelingen op het gebied van de angiogeneseremmers
Nieuwe ontwikkelingen op het gebied van de angiogeneseremmers Emile Voest, MD, PhD Department of Medical Oncology University Medical Center Utrecht the Netherlands 4e Nascholing Targeted Therapy April
More informationI've Just Been Diagnosed. with Kidney Cancer: What s Next?
I've Just Been Diagnosed with Cancer: What s Next? Table of Contents Introduction Message from a Survivor What are the s and What is Their Function? What is Cancer? What are the Types of Cancer? What are
More informationLEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationMiquel Àngel Seguí Palmer
Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with
More informationCome valutare la risposta o la progressione nei pazienti in trattamento con terapie biologiche
Come valutare la risposta o la progressione nei pazienti in trattamento con terapie biologiche Andrea Busolo U.O. di Radiologia Rocco De Vivo U.O. di Oncologia Medica ULSS 6 - Vicenza Activity and efficacy
More informationCompleted Clinical Research Trials Prema Abraham, M.D.
Completed Clinical Research Trials Prema Abraham, M.D. AMD Studies 2010 Present Principal Investigator: A Phase 2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous
More informationTargeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
More informationBiomarker Trends in Breast Cancer Research
WHITE PAPER Biomarker Trends in Breast Cancer Research Jason Hill, PhD, Associate Director, External Science Affairs, Quintiles Quintiles examines the novel drug combinations and mechanisms of action that
More informationAngiogenesis and Current Antiangiogenic Strategies for the Treatment of Cancer
Emerging Technologies Angiogenesis and Current Antiangiogenic Strategies for the Treatment of Cancer Rahmi Oklu, PhD, MD, Thomas G. Walker, MD, Stephan Wicky, MD, and Robin Hesketh, PhD Angiogenesis is
More informationClinical Cancer Research: Alternative IRB Models and Enhancing Progress
Clinical Cancer Research: Alternative IRB Models and Enhancing Progress Lowell E. Schnipper, M.D. Berenson Professor of Medicine Chief, Hematology-Oncology Beth Israel Deaconess Medical Dynamics of Clinical
More informationDemystifying Stem Cells. Brent Bost M.D., CPA, MBA, FACOG
Demystifying Stem Cells Brent Bost M.D., CPA, MBA, FACOG Disclaimers Author currently serves on Board of Directors of CordTrack Most applications discussed today are not currently FDA approved and are,
More informationBOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy 2014-05
Syndicated Thought Leader Insight Healthcare & Pharmaceutical Research Cancer Immunotherapy Melanoma, Non- Small Cell Lung Cancer, Renal Cell Carcinoma Thought Leader Panel #38 2014-05 Therapeutic Area:
More informationVersion 1 2015. Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen
Version 1 2015 Module guide International Master Program Cardiovascular Science University of Göttingen Part 1 Theoretical modules Synopsis The Master program Cardiovascular Science contains four theoretical
More informationDepartment of BioScience Technology Chung Yuan Christian University 2015/08/13
Department of BioScience Technology Chung Yuan Christian University 2015/08/13 Cancer Cells Cancer, the 1st leading cause of death, is an example of a disease that arises from abnormalities in cell function
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationKidney Cancer Research: Developing a New Vision for the Future
Kidney Cancer Research: Developing a New Vision for the Future A symposium for young investigators, hosted by the Kidney Cancer Association, September 7, 2011 Introduction Since the founding of the Kidney
More informationBayer Accelerates Clinical Development of Promising New Drug Candidates
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Accelerates Clinical Development of Promising New Drug Candidates Five
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationMédecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN
Médecine de précision médecine personnalisée en Oncologie Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN Successful targeted drug development Rapid identification
More informationProgress in the Treatment of Kidney Cancer
KIDNEY CANCER Progress in the Treatment of Kidney Cancer Presented by Ronald M. Bukowski, MD The Cleveland Clinic Foundation Keith Lyons, MSW CancerCare Find out about: Current treatment options New advances
More informationPrecision oncology: identifying predictive biomarkers for the treatment of metastatic renal cell carcinoma
Perspective Precision oncology: identifying predictive biomarkers for the treatment of metastatic renal cell carcinoma Parth K. Modi 1, Nicholas J. Farber 1, Eric A. Singer 1,2 1 Division of Urology, Rutgers
More informationThe Ultimate Healthcare & Biotechnology Event in 2010. Deborah Rathjen CEO & Managing Director 24 March 2010
The Ultimate Healthcare & Biotechnology Event in 2010 Deborah Rathjen CEO & Managing Director 24 March 2010 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking"
More informationBreast Cancer Drug Discoveries: What the Future Holds
Brochure More information from http://www.researchandmarkets.com/reports/679630/ Breast Cancer Drug Discoveries: What the Future Holds Description: In 2010, almost 50% of breast cancer sales were due to
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationCANCERCARE CONNECT BOOKLET SERIES. Kidney Cancer. www.cancercare.org
CANCERCARE CONNECT BOOKLET SERIES Treatment Update Kidney Cancer www.cancercare.org The CancerCare Connect Booklet Series offers up-to-date, easy-to-read information on the latest treatments, managing
More informationtargeted therapy a guide for the patient
targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting
More informationMedical Therapies Limited EGM Presentation
Medical Therapies Limited EGM Presentation Maria Halasz Chief Executive Officer 5 May 2009 1 Agenda 1. Company information 2. Recent developments 3. Business strategy 4. Key value inflection points for
More informationAngiogenesis. Physiological angiogenesis. Wound healing Ovulation
Physiological angiogenesis Angiogenesis Wound healing Ovulation Pathological angiogenesis cancer psoriasis arthritis blindness obesity asthma atherosclerosis infectious disease Menstruation Implantation
More informationThe Need for a PARP in vivo Pharmacodynamic Assay
The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D., Chief Scientific Officer, Trevigen, Inc., Gaithersburg, MD For further infomation, please contact: William Booth, Ph.D. Tel: +44 (0)1235
More informationAvastin (Bevacizumab) Intravitreal Injection
Avastin (Bevacizumab) Intravitreal Injection This handout describes how Avastin may be used to treat wet age related macular degeneration (AMD) or macular edema due to retinal vascular disease such as
More informationMULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationNeurotrophic factors and Their receptors
Neurotrophic factors and Their receptors Huang Shu-Hong Institute of neurobiology 1 For decades, scientists believed that brain cells of the central nervous system could not regrow following damage due
More informationPeptide and Sustained Release Technology to Treat Ocular Diseases and Cancer
Peptide and Sustained Release Technology to Treat Ocular Diseases and Cancer Jordan Green, PhD, Co-Founder and CEO Wendy Perrow, MBA, Senior Business Advisor February 11, 2015 www.asclepix.com Advantages
More informationRITMIR024 - STEM CELL RESEARCH IN CARDIOLOGY
1. SCOPE AND METHODOLOGY 2. REPORT SYNOPSIS 2.1 General Definitions Myoblasts Pluripotent Cells Multipotent Cells Progenitor Cells Role of Stem Cells in Repairing the Heart Stem Cell Therapy Stem Cells
More informationSmoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.
Renal cell cancer Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Renal cell cancer (also called kidney cancer or renal adenocarcinoma) is a disease in which
More informationLatest developments in management. Gianfilippo Bertelli Consultant Medical Oncologist Swansea
Latest developments in management Gianfilippo Bertelli Consultant Medical Oncologist Swansea Optimizing management of ovarian cancer in South Wales Diagnosis and referral pathways: Role of GPs, gynaecologists,
More informationMultiple Myeloma (Event Driven)
Brochure More information from http://www.researchandmarkets.com/reports/2234830/ Multiple Myeloma (Event Driven) Description: The 2010 multiple myeloma (myeloma) market garnered impressive sales despite
More informationHow To Treat Mesothelioma With A Tumor Stem Cell Inhibitor
FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS Rationale for maintenance therapy after conventional therapy Jonathan Pachter, Ph.D. Vice President of Research, Verastem, Inc.
More informationTranslocation Renal Cell Carcinomas
Translocation Renal Cell Carcinomas Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Kidney cancer is not a single disease Clear cell (75%)
More informationREPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM
REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)
More informationCytotoxic and Biotherapies Credentialing Programme Module 2
Cytotoxic and Biotherapies Credentialing Programme Module 2 1. The Cell Cycle 2. Cancer Therapies 3. Adjunctive Therapies On completion of this module the RN will State the difference between a normal
More informationTumori rari del rene: trattamento per stadio ed istologia Dr. Camillo Porta
Tumori rari del rene: trattamento per stadio ed istologia Dr. Camillo Porta S.C. di Oncologia Medica, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia Non-Clear Cell Renal Cell Carcinoma (nccrcc) nccrcc
More informationNEW BIOACTIVE PRODUCTS. B-RAF Inhibitors
B-RAF Inhibitors BAM66400 CHF 5074, 96+% 1mg: $300 A novel, potent and selective small molecule B-Raf kinase BAM66393 GDC-0879, BAM66396 PLX-4032 (RG7204/Vemurafenib/Zelboraf), 96+% BAM66397 PLX-4720,
More informationspecific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins
Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes
More informationtreatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can
Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods
More informationThe Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black
More informationUpdate on Clinical Trials and Foundation Funded Grants
Update on Clinical Trials and Foundation Funded Grants Mary Hesdorffer, MS, APRN-BC Medical Liaison Meso Foundation www.curemeso.org Delivering the Diagnosis Delivering the Diagnosis Day 1 Taking control
More informationTargeted Therapies in Lung Cancer
Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why
More informationZeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice
Lung Cancer: Integrating Targeted Therapies into Practice Table of Contents Program Information... 2 Faculty Biographies... 3 Genomic Profiling of NSCLC for EGFR Inhibitors... 4 Fred R. Hirsch, MD, PhD
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationSTEM CELL FELLOWSHIP
Module I: The Basic Principles of Stem Cells 1. Basics of Stem Cells a. Understanding the development of embryonic stem cells i. Embryonic stem cells ii. Embryonic germ cells iii. Differentiated stem cell
More informationSorafenib. Bernard ESCUDIER Institut Gustave Roussy Villejuif, France
Sorafenib for renal cell carcinoma Bernard ESCUDIER Institut Gustave Roussy Villejuif, France Renal Cell Carcinoma: Drugs and Targets pvhl = HIFα CCI-779 Bevacizumab VEGF KDR PDGF PDGFR TGFα EGFR Sunitinib,
More informationASCO Initiatives in Personalized Medicine. Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology
ASCO Initiatives in Personalized Medicine Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology Financial Disclosures No financial relationships to disclose.
More informationOvarian Cancer (Event Driven)
Brochure More information from http://www.researchandmarkets.com/reports/2367241/ Ovarian Cancer (Event Driven) Description: Owing to the lack of screening programs across the markets under study, ovarian
More informationCritical Pathways Forward in the Treatment of Renal Cell Carcinoma
Critical Pathways Forward in the Treatment of Renal Cell Carcinoma Based on an Expert Summit convened in Washington, DC, July 30-31, 2012 Key Points 1. The approval of seven agents, all targeting angiogenesis,
More informationBNC105 PHASE II RENAL CANCER TRIAL RESULTS
ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationNCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy
S-1 NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy Gary R. Hudes, MD; Michael A. Carducci, MD; Toni K. Choueiri, MD; Peg Esper, MSN, MSA,
More informationGenomic Analysis of Mature B-cell Malignancies
Genomic Analysis of Mature B-cell Malignancies Update and Lessons Learned Omar Abdel-Wahab, MD Memorial Sloan Kettering Cancer Center Human Oncology and Pathogenesis Program and Leukemia Service Disclaimer:
More informationPersonalized, Targeted Treatment Options Offer Hope of Multiple Myeloma as a Chronic Disease
/publications/targeted-therapy-news/2012/november-2012/personalized-targeted-treatment-options- Offer-Hope-of-Multiple-Myeloma-as-a-Chronic-Disease Personalized, Targeted Treatment Options Offer Hope of
More informationCancer patients waiting for potentially live-saving treatments in UK
Cancer patients waiting for potentially live-saving treatments in UK 29 May 2005 UK patients are waiting too long for new treatments, according to a 'Dossier of Delay' compiled by information charity CancerBACUP.
More informationNon Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
More informationA Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
More informationAffitech A/S reports financial result for the first six months of 2012
Release no. 23/2012 Affitech A/S reports financial result for the first six months of 2012 Clinical trials sites initiated in Russia in late June 2012 by Affitech s collaboration partner IBC Generium for
More informationThe following information is only meant for people who have been diagnosed with advanced non-small cell
Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC
More information